Gretchen Kimmick

Overview:

Breast cancer; treatment of breast cancer; management of menopausal symptoms in breast cancer survivors; survivorship issues after breast cancer; supportive care in managment of cancer patients; breast cancer and treatment of cancer in older persons; diagnosis and management of cancer in underserved populations.

Positions:

Professor of Medicine

Medicine, Medical Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 1989

Wake Forest University

M.S. 2000

Wake Forest University

Medical Resident, Medicine

University of Florida

Fellow in Oncology, Medicine

North Carolina Baptist Hospital

Grants:

A Phase II Study of Neratinib in Metastatic HER2 Non-amplified by HER2 Mutant Breast Cancer

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

Publications:

Patient-reported outcomes in the Translational Breast Cancer Research Consortium.

Members of the Translational Breast Cancer Research Consortium conducted an expert-driven literature review to identify a list of domains and to evaluate potential measures of these domains for inclusion in a list of preferred measures. Measures were included if they were easily available, free of charge, and had acceptable psychometrics based on published peer-reviewed analyses. A total of 22 domains and 52 measures were identified during the selection process. Taken together, these measures form a reliable and validated list of measurement tools that are easily available and used in multiple cancer trials to assess patient-reported outcomes in relevant patients.
Authors
Bowen, DJ; Shinn, EH; Gregrowski, S; Kimmick, G; Dominici, LS; Frank, ES; Smith, KL; Rocque, G; Ruddy, KJ; Pollastro, T; Melisko, M; Ballinger, TJ; Fayanju, OM; Wolff, AC
MLA Citation
Bowen, Deborah J., et al. “Patient-reported outcomes in the Translational Breast Cancer Research Consortium..” Cancer, Nov. 2019. Pubmed, doi:10.1002/cncr.32615.
URI
https://scholars.duke.edu/individual/pub1421501
PMID
31743427
Source
pubmed
Published In
Cancer
Published Date
DOI
10.1002/cncr.32615

A feasible and acceptable multicultural psychosocial intervention targeting symptom management in the context of advanced breast cancer.

OBJECTIVE: Advanced breast cancer patients around the world experience high symptom burden (ie, distress, pain, and fatigue) and are in need of psychosocial interventions that target symptom management. This study examined the feasibility, acceptability, and engagement of a psychosocial intervention that uses cognitive-behavioral strategies along with mindfulness and values-based activity to enhance patients' ability to manage symptoms of advanced disease in a cross-cultural setting (United States and Singapore). Pre-treatment to post-treatment outcomes for distress, pain, and fatigue were compared between intervention recipients and waitlisted controls. METHODS: A pilot randomized controlled trial included women with advanced breast cancer (N = 85) that were recruited in the United States and Singapore. Participants either received the four session intervention or were put on a waitlist. Descriptive statistics and effect size of symptom change were calculated. RESULTS: The psychosocial intervention was found to be feasible as indicated through successful trial accrual, low study attrition (15% ), and high intervention adherence (77% completed all sessions). Acceptability (ie, program satisfaction and cultural sensitivity) and engagement to the study intervention (ie, practice of skills taught) were also high. Anxiety, depression, and fatigue scores remained stable or improved among intervention participants while the same symptoms worsened in the control group. In general, effect sizes are larger in the US sample compared with the Singapore sample. CONCLUSIONS: The cognitive-behavioral, mindfulness, and values-based intervention is feasible, acceptable, and engaging for advanced breast cancer patients in a cross-cultural setting and has potential for efficacy. Further larger-scaled study of intervention efficacy is warranted.
Authors
Teo, I; Vilardaga, JP; Tan, YP; Winger, J; Cheung, YB; Yang, GM; Finkelstein, EA; Shelby, RA; Kamal, AH; Kimmick, G; Somers, TJ
MLA Citation
URI
https://scholars.duke.edu/individual/pub1421436
PMID
31703146
Source
pubmed
Published In
Psychooncology
Published Date
DOI
10.1002/pon.5275

Decreasing incidence of upper age restriction enrollment criteria among cancer clinical trials.

BACKGROUND: Age disparities among cancer clinical trial participants are pervasive and worsening over time. Identification of factors associated with age disparities is critical to improve enrollment of older patients on trials. The incidence and impact of trial eligibility criteria that exclude patients on the basis of age remains opaque. METHODS: ClinicalTrials.gov was queried for completed oncologic randomized controlled trials (RCTs). Phase 3 RCTs assessing a therapeutic intervention among adult cancer patients were included. Trial eligibility criteria were assessed using the ClinicalTrials.gov website as well as trial publications and protocol documentation. RESULTS: Seven hundred and forty-two trials met inclusion criteria, with a total combined enrollment of 449,720 patients. Upper age restriction enrollment criteria were identified for 10.1% of RCTs; the median age cutoff for restricted trials was 72 years (interquartile range 70-80 years). Linear regression modeling revealed decreasing incidence of age restriction criteria over time, at a rate of -1.1% annually (p = .03); trials initiating enrollment in 2002-2005, for example, had a 16.1% rate of age-restrictive eligibility criteria, compared with 7.6% for trials initiating enrollment in 2010-2014. CONCLUSION: Use of eligibility criteria that explicitly exclude patients on the basis of age appears to be decreasing with time. Future efforts should aim to better characterize the relationship between eligibility criteria (such as those that exclude patients on the basis of specific organ function) and their association with age disparities among enrolled patients.
Authors
Ludmir, EB; Subbiah, IM; Mainwaring, W; Miller, AB; Lin, TA; Jethanandani, A; Espinoza, AF; Mandel, JJ; Fang, P; Smith, BD; Smith, GL; Pinnix, CC; Sedrak, MS; Kimmick, GG; Stinchcombe, TE; Jagsi, R; Thomas, CR; Fuller, CD; VanderWalde, NA
MLA Citation
Ludmir, Ethan B., et al. “Decreasing incidence of upper age restriction enrollment criteria among cancer clinical trials..” J Geriatr Oncol, Nov. 2019. Pubmed, doi:10.1016/j.jgo.2019.11.001.
URI
https://scholars.duke.edu/individual/pub1421647
PMID
31711757
Source
pubmed
Published In
J Geriatr Oncol
Published Date
DOI
10.1016/j.jgo.2019.11.001

Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer.

OBJECTIVES: To analyze self-reported changes in physical function in older women with breast cancer receiving adjuvant chemotherapy. DESIGN: Secondary analysis of the Cancer and Leukemia Group B (CALGB) 49907 prospective randomized clinical trial. SETTING: CALGB institutions in the United States. PARTICIPANTS: Women aged 65 and older with Stage I to III breast cancer enrolled in CALGB 49907 who had physical function data from before and after receipt of adjuvant chemotherapy (N=256; mean age 71.5, range 65-85). MEASUREMENTS: Participants were administered the physical function subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire before chemotherapy, at the end of chemotherapy, and 12 months after chemotherapy initiation. Functional decline was defined as a more than 10-point decrease from baseline at each time point. Resilience was defined as return to within 10 points of baseline. Multivariable regression was used to examine pretreatment characteristics associated with physical function changes. RESULTS: Of 42% of participants who had physical function decline from before to the end of chemotherapy, 47% recovered by 12 months (were resilient). Almost one-third experienced functional decline from before chemotherapy to 12 months later. Pretreatment fatigue was a risk factor for functional decline from before to the end of chemotherapy (P=.02). Risk factors for functional decline at 12 months included pretreatment dyspnea (P=.007) and being unmarried (P=.01). CONCLUSION: Functional decline was common in older women receiving adjuvant chemotherapy for breast cancer in a clinical trial. Although half recovered their physical function, one-third had a clinically meaningful decline at 12 months. Strategies are needed to prevent functional decline in older adults receiving chemotherapy. J Am Geriatr Soc 67:920-927, 2019.
Authors
Hurria, A; Soto-Perez-de-Celis, E; Allred, JB; Cohen, HJ; Arsenyan, A; Ballman, K; Le-Rademacher, J; Jatoi, A; Filo, J; Mandelblatt, J; Lafky, JM; Kimmick, G; Klepin, HD; Freedman, RA; Burstein, H; Gralow, J; Wolff, AC; Magrinat, G; Barginear, M; Muss, H
MLA Citation
Hurria, Arti, et al. “Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer..” J Am Geriatr Soc, vol. 67, no. 5, May 2019, pp. 920–27. Pubmed, doi:10.1111/jgs.15493.
URI
https://scholars.duke.edu/individual/pub1346482
PMID
30146695
Source
pubmed
Published In
Journal of the American Geriatrics Society
Volume
67
Published Date
Start Page
920
End Page
927
DOI
10.1111/jgs.15493

Epidemiology of cardio-oncology

Authors
Lenneman, CG; Kimmick, GG; Sawyer, DB
MLA Citation
Lenneman, C. G., et al. “Epidemiology of cardio-oncology.” Cardio-Oncology: The Clinical Overlap of Cancer and Heart Disease, 2017, pp. 1–14. Scopus, doi:10.1007/978-3-319-43096-6_1.
URI
https://scholars.duke.edu/individual/pub1286610
Source
scopus
Published Date
Start Page
1
End Page
14
DOI
10.1007/978-3-319-43096-6_1